Last reviewed · How we verify
Anti-CD20 antibody
Anti-CD20 antibody is a Monoclonal antibody (anti-CD20) Small molecule drug developed by The University of Hong Kong. It is currently in Phase 3 development for B-cell non-Hodgkin lymphoma, Chronic lymphocytic leukemia, Autoimmune diseases (e.g., rheumatoid arthritis, pemphigus vulgaris). Also known as: rituximab or biosimilar.
Anti-CD20 antibodies bind to CD20 antigen on B cells, leading to B cell depletion through antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and direct induction of apoptosis.
Anti-CD20 antibodies bind to CD20 antigen on B cells, leading to B cell depletion through antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and direct induction of apoptosis. Used for B-cell non-Hodgkin lymphoma, Chronic lymphocytic leukemia, Autoimmune diseases (e.g., rheumatoid arthritis, pemphigus vulgaris).
At a glance
| Generic name | Anti-CD20 antibody |
|---|---|
| Also known as | rituximab or biosimilar |
| Sponsor | The University of Hong Kong |
| Drug class | Monoclonal antibody (anti-CD20) |
| Target | CD20 |
| Modality | Small molecule |
| Therapeutic area | Oncology, Immunology |
| Phase | Phase 3 |
Mechanism of action
CD20 is a surface antigen expressed on B lymphocytes from the pre-B cell stage through mature B cells but absent on hematopoietic stem cells and plasma cells. By targeting CD20, these antibodies selectively eliminate B cells, reducing autoimmune responses and abnormal B cell proliferation. This mechanism is effective in both B-cell malignancies and autoimmune diseases where B cells play a pathogenic role.
Approved indications
- B-cell non-Hodgkin lymphoma
- Chronic lymphocytic leukemia
- Autoimmune diseases (e.g., rheumatoid arthritis, pemphigus vulgaris)
Common side effects
- Infusion reactions
- Infections
- Cytopenias
- Fatigue
- Fever
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia (PHASE1, PHASE2)
- Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial (PHASE2)
- Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma (PHASE2)
- A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies (PHASE1)
- Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (PHASE3)
- Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma (PHASE1)
- Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-CD20 antibody CI brief — competitive landscape report
- Anti-CD20 antibody updates RSS · CI watch RSS
- The University of Hong Kong portfolio CI
Frequently asked questions about Anti-CD20 antibody
What is Anti-CD20 antibody?
How does Anti-CD20 antibody work?
What is Anti-CD20 antibody used for?
Who makes Anti-CD20 antibody?
Is Anti-CD20 antibody also known as anything else?
What drug class is Anti-CD20 antibody in?
What development phase is Anti-CD20 antibody in?
What are the side effects of Anti-CD20 antibody?
What does Anti-CD20 antibody target?
Related
- Drug class: All Monoclonal antibody (anti-CD20) drugs
- Target: All drugs targeting CD20
- Manufacturer: The University of Hong Kong — full pipeline
- Therapeutic area: All drugs in Oncology, Immunology
- Indication: Drugs for B-cell non-Hodgkin lymphoma
- Indication: Drugs for Chronic lymphocytic leukemia
- Indication: Drugs for Autoimmune diseases (e.g., rheumatoid arthritis, pemphigus vulgaris)
- Also known as: rituximab or biosimilar
- Compare: Anti-CD20 antibody vs similar drugs
- Pricing: Anti-CD20 antibody cost, discount & access